方法：回顾性分析2013-01/2015-12期间在佛山市第二人民医院眼科中心的住院患者，以手术方式为“玻璃体腔内注药术”为检索词查阅病历管理系统，排除玻璃体腔注射曲安奈德及抗生素药物的患者，就其相关疾病进行统计分析。同时查询相关疾病同年收住院患者资料并进行对比。

结果：3a间共行239眼注射，男女比例接近，青年、中年及老年组间无统计学差异，3a间注射人数逐年增加。行抗VEGF(vascular endothelial growth factor)注射的相关疾病主要为脉络膜新生血管性疾病、视网膜静脉阻塞、糖尿病性视网膜病变及息肉状脉络膜血管病变，同一年度四类疾病及同种疾病不同年度行抗VEGF注射比率(注射/总数)有显著性统计学差异，其中脉络膜新生血管性疾病患者3a中接受注射程度最高，息肉状脉络膜血管病变则增长最快。

结论：抗VEGF玻璃体腔注射作为眼底新生血管性疾病新的治疗方式，正日益为患者接受。

METHODS: Retrospective analysis of inpatients of Foshan Second People's Hospital from January 2013 to December 2015, searched the inpatient management system with the term "intravitreal injection", excluded patients with intravitreal injection of TA and antibiotics, and queried the diseases involved. Then summarized the amount of inpatients of each disease as comparison.

RESULTS: Totally 239 eyes underwent injection in 3a. The proportion of male and female was even. No statistical difference among the youth,the middle age and the old group. The amount of injections was increased year by year. The main diseases underwent anti-VEGF injection was retinal vein occlusion(RVO), choroidal neovascularization retinopathy(CNV), diabetic retinopathy(DR)and polypoidal choroidal vasculopathy(PCV). Anti-VEGF injection ratio(injection/total)of the four diseases in the same year and each disease of different year were significantly statistic different. Among the four main disease, anti-VEGF injection was the most accepted in CNV patients, and anti-VEGF injection ratio was the most improved in PCV patients.

CONCLUSION: Anti-VEGF intravitreal injection as a new treatment for fundus neovascular diseases was increasingly accepted by patients.